StemRIM Inc. (JP:4599)
:4599
Want to see JP:4599 full AI Analyst Report?
4599 Stock Chart & Stats
¥255.00
-¥6.00(-1.94%)
At close: 4:00 PM EST
¥255.00
-¥6.00(-1.94%)
Day’s Range― - ―
52-Week Range¥246.00 - ¥360.00
Previous CloseN/A
Volume121.60K
Average Volume (3M)122.86K
Market Cap
¥19.87B
Enterprise Value¥15.04B
Total Cash (Recent Filing)¥6.99B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Jun 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.42
Shares Outstanding62,681,200
10 Day Avg. Volume118,910
30 Day Avg. Volume122,863
Financial Highlights & Ratios
PEG Ratio1.85
Price to Book (P/B)2.69
Price to Sales (P/S)0.00
P/FCF Ratio-13.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-30.8
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet FlexibilityNear-zero debt materially reduces default risk and preserves strategic optionality. For a biotech firm facing long development cycles, minimal leverage provides durable flexibility to fund trials, pursue collaborations, or endure setbacks without immediate solvency pressure, improving runway for strategic initiatives.
Licensing & Collaboration Revenue ModelAn asset-light licensing and collaboration model can produce recurring milestone and royalty streams while shifting development cost and commercialization risk to partners. Structurally, this model supports scalability and capital efficiency, letting the company leverage partners' commercial capabilities over the medium term.
Proprietary Regenerative Medicine TechnologyProprietary stem-cell and regeneration technologies create a defensible niche in high-barrier therapeutic areas. Structural demand from aging populations and limited competition in certain regenerative indications imply sustainable long-term market opportunity if clinical progress and partner uptake resume.
Bears Say
Revenue Disappearance And Loss-makingA drop to zero reported revenue across two years signals loss of recurring licensing or one-time income and undermines visibility. Combined with multi-year large net losses, this structural revenue gap threatens the firm's ability to sustain operations and attract long-term partners without new income sources.
Sustained Operating Cash Burn And Negative FCFMaterial negative operating cash flow and persistent negative free cash flow indicate the company is not self-sustaining and depends on balance sheet resources or external financing. Over months, this raises refinancing and dilution risk and constrains ability to fund trials or commercialization without partner funding.
Eroding Equity BaseDeclining shareholders' equity over consecutive years shows accumulated losses are consuming the capital cushion. This reduces the buffer against clinical setbacks or prolonged commercialization timelines and limits borrowing capacity, making durable recovery dependent on reversing losses or securing material external capital.
StemRIM Inc. News
4599 FAQ
What was StemRIM Inc.’s price range in the past 12 months?
StemRIM Inc. lowest stock price was ¥246.00 and its highest was ¥360.00 in the past 12 months.
What is StemRIM Inc.’s market cap?
StemRIM Inc.’s market cap is ¥19.87B.
When is StemRIM Inc.’s upcoming earnings report date?
StemRIM Inc.’s upcoming earnings report date is Jun 17, 2026 which is in 58 days.
How were StemRIM Inc.’s earnings last quarter?
StemRIM Inc. released its earnings results on Mar 11, 2026. The company reported -¥6.42 earnings per share for the quarter, missing the consensus estimate of N/A by -¥6.42.
Is StemRIM Inc. overvalued?
According to Wall Street analysts StemRIM Inc.’s price is currently Overvalued.
Does StemRIM Inc. pay dividends?
StemRIM Inc. does not currently pay dividends.
What is StemRIM Inc.’s EPS estimate?
StemRIM Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does StemRIM Inc. have?
StemRIM Inc. has 62,681,200 shares outstanding.
What happened to StemRIM Inc.’s price movement after its last earnings report?
StemRIM Inc. reported an EPS of -¥6.42 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.333%.
Which hedge fund is a major shareholder of StemRIM Inc.?
Currently, no hedge funds are holding shares in JP:4599
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
StemRIM Inc.
StemRIM, a biotechnology company, develops regeneration medicines for the treatment of intractable diseases. It develops PJ1, a regeneration induction medicine HMGB1 peptides, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, osteoarthritis, and chronic liver disease, as well as cardiomyopathy; PJ2, a regeneration-inducing medicine novel peptides A and B; PJ3, a biologic regeneration-inducing protein; PJ4, an autologous cell sampling device for medical treatment; and PJ5, a stem cell gene therapy. StemRIM was incorporated in 2006 and is based in Ibaraki, Japan.
Technical Analysis
Healios KK
―
CellSource Co., Ltd.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―